China Resources Pharmaceutical Group Limited (CR Pharma; HKEX: 03320) has disclosed the unaudited results of its 29.08%-owned subsidiary KPC Pharmaceuticals, Inc. (KPC) for the nine months ended 30 September 2026.

Revenue and Profitability • KPC reported revenue of RMB 2.72 billion, down 42.7% from RMB 4.75 billion a year earlier. • The company posted a net loss of RMB 0.36 billion, reversing the prior period’s net profit of RMB 0.32 billion.

Cash Flow and Liquidity • Net cash outflow reached RMB 0.76 billion, an improvement on the RMB 1.41 billion outflow recorded in the same period last year. • Cash and cash equivalents stood at RMB 0.37 billion at period-end, compared with RMB 0.72 billion a year earlier.

Balance Sheet Position (as at 30 September 2026) • Total assets: RMB 10.52 billion, down 10.6% from RMB 11.77 billion at 31 December 2025. • Total liabilities: RMB 4.08 billion, down 15.6% from RMB 4.83 billion. • Owner’s equity: RMB 6.44 billion, down 7.2% from RMB 6.94 billion.

Accounting Basis and Status The figures are prepared under PRC GAAP, remain unaudited, and may be adjusted during the audit process. They relate solely to KPC and do not represent the consolidated performance of CR Pharma.

Investors are advised to review KPC’s full quarterly report on the Shanghai Stock Exchange website and exercise caution when dealing in CR Pharma securities.